BridgeBio Oncology Therapeutics Price Chart
BridgeBio Oncology Therapeutics Volume Chart
BridgeBio Oncology Therapeutics Market Segments
After Hours
+0.06(+0.72%)
| Open | $8.34 |
|---|---|
| Close | $8.40 |
| Low | $8.34 |
| Low Change | 0.00 (0.00%) |
| High | $8.40 |
| High Change | +0.06 (+0.72%) |
| Range | $0.06 |
| Volume | 987 |
| Dollar Volume | $8.29K |
Regular Trading Hours
+0.16(+1.91%)
| Open | $8.37 |
|---|---|
| Close | $8.53 |
| Low | $8.06 |
| Low Change | -0.31 (-3.70%) |
| High | $8.55 |
| High Change | +0.18 (+2.15%) |
| Range | $0.49 |
| Volume | 778.84K |
| Dollar Volume | $6.64M |
Premarket
*No Trades in Segment
After Hours Yesterday
*No Trades in Segment
Regular Trading Hours Yesterday
+0.43(+5.27%)
| Open | $8.09 |
|---|---|
| Close | $8.52 |
| Low | $7.70 |
| Low Change | -0.39 (-4.82%) |
| High | $8.63 |
| High Change | +0.54 (+6.67%) |
| Range | $0.93 |
| Volume | 315.797K |
| Dollar Volume | $2.69M |
Premarket Yesterday
*No Trades in Segment
BridgeBio Oncology Therapeutics Moving Averages
| 5 Day Moving Average (SMA5) | $8.04 |
|---|---|
| 10 Day Moving Average (SMA10) | $8.15 |
| 20 Day Moving Average (SMA20) | $8.51 |
| 50 Day Moving Average (SMA50) | $8.90 |
| 100 Day Moving Average (SMA100) | $10.22 |
| 200 Day Moving Average (SMA200) | — |
BridgeBio Oncology Therapeutics Statistics
| Average Volume (30 Days) | 435.13K |
|---|---|
| P/E Ratio (Current) | -7.77 |
| EPS (Current) | -$1.04 |
| Dividend Yield | 0.00% |
| Free Cash Flow | -$114.50M |
| Cash Ratio | 10.66 |
| Current Ratio | 12.34 |
| Quick Ratio | 12.34 |
| Debt to Equity | 0.00 |
| Enterprise Value | $273.58M |
| EV to EBITDA | -2.86 |
| EV to Sales | 75909.66 |
| Price to Book | 1.57 |
| Price to Cash Flow | — |
| Price to Free Cash Flow | — |
| Price to Sales | 179596.39 |
| Return on Assets | -0.19% |
| Return on Equity | -0.20% |
BridgeBio Oncology Therapeutics Stock Splits
There have been no stock splits for BridgeBio Oncology Therapeutics (BBOT).
BridgeBio Oncology Therapeutics Dividends
There have been no dividends for BridgeBio Oncology Therapeutics (BBOT).